Biocept - Model EGFR - Target Selector Mutation Test Kit
From Target Selector Kits (US)
This kit detects EGFR mutations in DNA derived from blood plasma or FFPE tissue sections to give insight into cancer characteristics and provide Biomarker status of tumors such as non-small cell lung cancer.
-
Most popular related searches
Product Details
Benefits of Biocept Target Selector™ Switch-Blocker Technology
- Enrichment of cancer biomarker mutations (Del19, L858R, T790M) in a high wild-type background
- Suppression of wild-type DNA amplification
- Proofreading DNA Polymerase resulting in lower false positives
- Avoids damaged DNA templates (such as deaminated cytosines)
- Ultra-high sensitivity and specificity
- Combination with Sanger sequencing for orthogonal verification of the enriched mutation
- Detection of Del19, L858R, T790M as well as Wild-Type are quantitative
ctDNA Performance
- Sensitivity: 0.05% mutant allele fraction -single copy detection of mutant in up to 14000 copies of wild-type DNA background
- Specificity: >99%
- Effective range of DNA input: 10pg-50ng DNA
FFPE DNA Performance
- Eliminates need for macrodissection of FFPE tissue by enriching mutations and blocking wild-type DNA amplification
- Sensitivity thresholds have been established to account for artifacts introduced by formaldehyde fixation
- Mutant allele frequencies below these cut-offs are considered negative for the mutation
- Del19 cutoff: 0.17%
- L858R cutoff: 0.17%
- T790M cutoff: 2.87%
- Specificity: >98.4%
- Effective range of DNA input: 10pg-50ng DNA
These thresholds are provided as a guideline but every research facility/laboratory should establish their own thresholds based on their own criteria.
General Specifications
- Stability: 1 year
- Storage: 20°C
Customer reviews
No reviews were found for Biocept - Model EGFR - Target Selector Mutation Test Kit. Be the first to review!